Nektar Therapeutics (NKTR) to Release Quarterly Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) is scheduled to announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its quarterly earnings data on Monday, March 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.01). The business had revenue of $23.89 million during the quarter, compared to the consensus estimate of $17.09 million. Nektar Therapeutics had a negative return on equity of 96.80% and a negative net margin of 306.31%. During the same quarter last year, the company earned ($0.32) EPS. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nektar Therapeutics Trading Down 6.0 %

NASDAQ NKTR traded down $0.10 on Friday, hitting $1.57. 1,140,501 shares of the company traded hands, compared to its average volume of 2,097,770. The business's 50 day moving average price is $1.10 and its 200-day moving average price is $0.73. The company has a market capitalization of $288.28 million, a price-to-earnings ratio of -1.18 and a beta of 0.71. Nektar Therapeutics has a 52-week low of $0.41 and a 52-week high of $1.79.

Analysts Set New Price Targets

Several analysts have recently commented on NKTR shares. StockNews.com began coverage on shares of Nektar Therapeutics in a research report on Friday, January 26th. They set a "hold" rating on the stock. William Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a research note on Tuesday, March 5th. Finally, Jefferies Financial Group increased their price objective on shares of Nektar Therapeutics from $0.50 to $1.00 and gave the company a "hold" rating in a research report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, Nektar Therapeutics has an average rating of "Hold" and an average target price of $3.50.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.